SARASOTA, Fla., June 23, 2020 — INVO Bioscience, Inc. (OTCQB: INVO), (“the Company”) a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell^®, the world’s only in vivo Intravaginal Culture System, announced that the company will trade under the symbol “INVO” effective at the beginning of trading on Tuesday, June 23, 2020. For the period May 26, 2020 through June 22, 2020 the company had traded under the symbol “INVOD” following the previously announced reverse stock split. The Company had previously announced on May 22, 2020 that it had effected a 1-for-20 reverse stock split reducing the amount of issued and outstanding common shares to approximately 7.89 million common shares. The reverse split was previously approved by the Company’s Board of Directors pursuant to the authority granted by the Company’s stockholders at the Company’s annual shareholder meeting held on December 16, 2019.

As a reminder, the Company’s transfer agent, Transfer Online, Inc., is the exchange agent for the reverse stock split and will correspond with stockholders of record holding physical certificates regarding the reverse stock split. Transfer Online, Inc. can be reached at 503-227-2950. Stockholders owning shares in book-entry form via a broker or other nominee need not take any action in connection with the reverse split and their positions have already automatically been adjusted to reflect the reverse stock split. Beneficial holders are encouraged to contact their bank, broker or custodian with any procedural questions.

“We are pleased to have completed this step toward improving the capitalization structure of the Company and overall visibility to the investor community. We are experiencing increased interest in our INVOcell device from prospective partners, physicians, patients, investors and media. We are steadfast in our mission to increase access to care and expand fertility treatment across the globe with a goal of lowering costs while increasing the availability of care to this dramatically underserved market. We also continue to ramp our commercialization efforts, which we believe will help to expand our international opportunities,” commented Steve Shum, CEO of INVO Bioscience.

Click here for the recent CEO interview with Vista Partners.

About INVO Bioscience

We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:http://www.prnewswire.com/news-releases/invo-bioscience-now-trading-under-invo-ticker-symbol-on-tuesday-june-23-2020-301081658.html

SOURCE INVO Bioscience, Inc.